2025 Flu Season 2025. One Step Closer to a Universal Flu Vaccine? The New York Times The key changes to the flu vaccination programme for the 2024 to 2025 flu season are: •change to recommendations as to when the flu vaccine should be given •change to the live attenuated influenza vaccine (LAIV) from a quadrivalent to a trivalent vaccine •the recombinant quadrivalent influenza vaccine (QIVr) will not be available for the Today, the FDA made recommendations to vaccine manufacturers for the virus strains to be used in the trivalent (three strain) flu vaccines for the 2025-2026 U.S
Preliminary Estimated Flu Disease Burden 20232024 Flu Season Flu Burden CDC from www.cdc.gov
Providers should ensure they complete these data returns through ImmForm during the appropriate time windows throughout the season The announcement was made at an information session at the end of a 4-day meeting on the Composition of Influenza Virus Vaccines, a meeting that is held twice annually.
reporting of the weekly influenza vaccine uptake for the 2024 to 2025 season has concluded (up to the end of week 4 ending 26 January 2025, vaccine uptake was 39.7% for those under 65 years in a. Ordering copies of flu resources 12 Annual flu programme resources 2024 to 2025 Paper copies of most resources are available to order at: www.healthpublications.gov.uk During the 2025 to 2026 flu immunisation programme monthly data.
About This Year's Flu Maricopa County, AZ. Today, the FDA made recommendations to vaccine manufacturers for the virus strains to be used in the trivalent (three strain) flu vaccines for the 2025-2026 U.S The key changes to the flu vaccination programme for the 2024 to 2025 flu season are: •change to recommendations as to when the flu vaccine should be given •change to the live attenuated influenza vaccine (LAIV) from a quadrivalent to a trivalent vaccine •the recombinant quadrivalent influenza vaccine (QIVr) will not be available for the
Flu Season is coming Communicating Science (14w112). BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the. Make recommendations on the composition of influenza virus vaccines for use in the 2025-2026 northern hemisphere influenza season; and Review the antigenic and genetic characteristics of recent A(H5/H9) and other subtype or variant zoonotic influenza viruses) that the WHO Collaborating Centres of the GISRS received and the need to develop new candidate vaccine viruses for pandemic preparedness.